Navigation Links
Reportlinker Adds All Change in the Coronary Stent Market

NEW YORK, Aug. 31 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

All Change in the Coronary Stent Market

Use this report to…

Review the prospects for key stent sectors

Evaluate how the market is developing

Know the current size and split in major regions and technology sectors

Know the market shares and performance of leading players

Understand how new applications could affect the market

Contrast and compare the competitive landscape in terms of product offering by stent sector

Understand the growth drivers and dampeners that will affect the market's development

Compare and review the research in new areas such as bioabsorbable and polymer-free stents.

All major current and future stent technologies are covered

Bare metal



Bioabsorbable polymer


Bifurcation applications

Unique 5-year sales forecasts for major stent sectors

A comprehensive examination of all current technologies, products and companies

Detailed evaluation of new technologies and the companies developing them

The development of the coronary stent market is dependent on the number of people with Coronary Artery Disease (CAD) requiring treatment. The number of Percutaneous Coronary Interventions (PCI) procedures performed, the percentage of PCIs in which stents are used, the number of stents used in each procedure and average selling prices for stents, all influence market values. In addition, whether a Bare Metal Stent (BMS) or Drug-Eluting Stent (DES) is used in the procedure impacts the market, as DESs command a much higher selling price than BMSs, while increased competition in the DES market has a major impact on the price companies can command for their DES products.

A recovering sector...

The coronary stent sector was knocked back when, in 2006, there emerged safety fears regarding the use of DESs when some longer-term clinical data indicated there was a small risk of late stent thrombosis for DES patients. It is believed this risk of late stent thrombosis relates to the use of a polymer on the DES and potentially the doses of drug used, both of which impair re-endothelialisation. While endothelialisation can take place within two months for a BMS, it can take up to a year for this process to be completed when a DES is used.

...Looking to a new generation of technology

The industry has responded with a range of new approaches, and the next-generation technologies have received much interest from the medical community due to their potential to address the problems of current coronary stents. These products would also be able to command a higher selling price than current stents and competition for the products would initially be limited. However, as relatively new products with little clinical and longer-term safety data, their potential for success cannot be assured. It therefore remains to be seen if they can reinvigorate the market for coronary stents and provide an effective alternative to current products.

The coronary stent market is expected to exceed US$5.3 billion by 2015 but new technologies must surmount clinical and regulatory hurdles

A regional perspective

Unlike many medical technology sectors, the coronary stent market is not reliant on the USA – this is both a limitation and an opportunity. Since clinical and regulatory concerns over stent safety emerged in 2006, the number of procedures has fallen, although numbers are recovering now. Even so, in 2009 the leading region for the number of PCI procedures was Europe with 1,230,000, a 39% share of the global market. While around 30 companies now have DES products available, only four have a DES available in either Japan or the US, which represent the largest two markets for such products.

Advanced technology will drive the sector

Given the limitations of currently-available coronary stenting products, which include higher rates of restenosis for BMSs and the potential for thrombosis for DESs, there is currently a major drive by manufacturers to develop products that improve on these designs. There are three main approaches being undertaken by coronary stent manufacturers, which can be summarised as follows:-

Polymer-free DESs –

These entirely eliminate use of the polymer, which is believed to lead to increased rates of thrombosis. Instead, these products include coatings or surface modification technologies that control drug elution. Only four companies are developing or sell such a product, mainly due to the difficulties of developing a product that does not release the drug too quickly without the polymer in place to control drug elution.

Bioabsorbable polymer DESs –

These include a BMS, a drug and a polymer that biodegrades once it has eluted the drug. In the longer-term, only a BMS is left in place in the vessel. These products are currently the most widely-developed next-generation stenting technologies. They offer the benefit of continuing to have a polymer to control drug elution, but one that is not left in the body over the longer-term. The idea is that once the polymer has dissolved, the risk of thrombosis would be reduced and patients would not require long-term dual anti-platelet therapy.

Bioabsorbable BMSs and DES –

These are stents that totally dissolve after a certain period of time. The aim is to provide the initial scaffolding needed by the vessel and to reduce the risk of restenosis, but then the stent would dissolve, leaving a natural, healed vessel. The main challenge is the development of a suitable stent material that can provide the initial strength required, not dissolve too quickly and not fail on deployment or as its properties change.




Percutaneous Coronary Intervention and the COURAGE Trial

Fig.1: Number of PCI Procedures Undertaken by Region, 2009

Fig.2: Number of PTCA Procedures Undertaken in the US, 2000-2007

Number of PTCA and CABG Procedures Undertaken in US Hospitals, 2000-2007

United Kingdom

Fig.3: PCI Procedures Undertaken in the UK, 2005-2008

Fig.4: UK PCI Procedures, Per million of the Population, 2005-2008

Fig.5: UK PCI Rates Per million of the Population by Country, 2009

Bare Metal Versus Drug-Eluting Stents

Fig.6: Global Coronary Stent Market by Product Type, 2009


Major Manufacturers' Coronary Stent Revenue, 2006-2009 (US$ million)

Fig.7: Coronary Stent Market Share by Company, 2009

Major Manufacturers' US Coronary Stent Revenue, 2006-2009 (US$ million)

Major Manufacturers' International Coronary Stent Revenue, 2006-2009 (US$ million)

Patent Litigation

Abbott v Medtronic and evYsio Medical Devices

Boston Scientific v Cordis

Boston Scientific v Medtronic

Cordis v Medtronic

Johnson & Johnson v Abbott

OrbusNeich v Boston Scientific

Medinol v Abbott

Industry Consolidation and Collaboration


Diabetes Prevalence, 2000 and 2030

Fig.8: Coronary Stent Market, 2009-2015(E) (US$ million)

Coronary Stent Market Growth Rates, 2010-2015(E) (%)


Leading Manufacturers' BMS Sales, 2006-2009 (US$ million)

Fig.9: Global BMS Market Shares by Company, 2009

Fig.10: BMS Market, 2007-2015(E) (US$ million)

Fig.11: Global BMS Market by Region, 2009


Competitive Landscape: Bare Metal Coronary Stents

New Products

Abbott's Multi-Link 8

Atrium Medical's Cinatra CoCr Stent

Biotronik's PRO-Kinetic Coronary Stents

CID's Avantgarde CoCr Carbostent

ClearStream Technologies' SatinFlex

CorNova's Valecor Platinum Coronary Stent System

DISA Vascular's SolarFlex

euatech's Camouflage Stent System

Hexacath's Titan2 BAS

InspireMD's MGuard Stent with Embolic Protection

ITGI Medical's Over and Under Pericardium Covered Stent

Medinol's Presillion and Presillion Plus CoCr Coronary Stents

Medlogics Device's Cobra Coronary Stent System

Medtronic's Driver Stents

Medtronic's Integrity

OrbusNeich's Genous Bio-engineered R stent

Prescient Medical's vProtect Luminal Shield

Stentys' Self-Expanding Stent

Translumina's Yukon CC

Products in Development

Palmaz Scientific's Nanotechnology-Based Stents

Svelte Medical Systems' Stent-on-a-Wire Stent

Veryan Holdings' BioMimics 3D Stent


Fig.12: Global DES Market, 2006-2009 (US$ billion)

DESs and Late Stent Thrombosis

DAPT Study


Major Manufacturers' DES Revenue, 2005-2009 (US$ million)

Major Manufacturers' Quarterly DES Revenue, 2008-Q1 2010 (US$ million)

Fig.13: Global DES Market Share Data, 2006-2009 (%)

Drug-Device Combinations

Competitive Landscape: Pharmaceuticals Used in Drug-Eluting Stents


Fig.14: DES Market by Region, 2009

United States

Fig.15: US Market: Quarterly DES Penetration Rates, 2008-2009 (%)

Fig.16: US DES Market Share Data, 2007-2009 (%)

Fig.17: US DES Market Share by Product, 2009

Fig.18: US DES Market Share by Company, 2009

Fig.19: US DES Market Share by Company, Q1 2010

Major Manufacturers' US DES Revenue, 2006-2009 (US$ million)

Major Manufacturers' Quarterly US DES Revenue, 2008-Q1 2010 (US$ million)

International Market

Selected Manufacturers' OUS DES Revenue, 2006-2009 (US$ million)

Selected Manufacturers' Quarterly OUS DES Revenue, 2008-Q1 2010 (US$ million)


Fig.20: Japan: DES Market Share by Company, 2009

Fig.21: Japan: DES Market Share by Product, Q1 2010

Fig.22: Japan: DES Market Share by Company, Q1 2010

United Kingdom

Fig.23: Percentage of PCI Cases Using DESs in the UK, 2003-2008


Fig.24: Global DES Market, 2007-2015(E) (US$ million)


Currently-Available Durable Polymer DESs

Aachen Resonance's Vita Tretinoin-eluting Coronary Stent

Abbott's Xience Everolimus-Eluting Coronary Stent Systems

Abbott's DES Sales, 2007-2009 (US$ million)

Fig.25: Abbott's DES Quarterly Sales Data, 2008-Q1 2010 (US$ million)

Fig.26: Promus Quarterly Sales Data, 2008-Q1 2010 (US$ million)

Fig.27: Promus Sales by Region, Q4 2009

Xience V

Xience Clinical Trials

Xience Prime

amg International's Pico Elite

B Braun's Coroflex Please

Boston Scientific's Drug-Eluting Coronary Stents

Boston Scientific DES Sales, 2004-2009 (US$ million)

Boston Scientific DES Sales by Product Line, 2007-2009 (US$ million

Fig.28: Boston Scientific DES Sales by Region, 2009

Fig.29: Boston Scientific DES Sales by Product, 2009

Fig.30: BSCI: Quarterly Sales Data, 2008-Q1 2010 (US$ million)

Fig.31: BSCI: Quarterly International Sales by Region, 2009 (US$ million)

Fig.32: Taxus Quarterly Sales Data, 2008-Q1 2010 (US$ million)

Fig.33: Taxus Sales by Region, Q4 2009

Taxus Express2 Paclitaxel-Eluting Stent System

TAXUS Clinical Trials




Taxus Liberte

TAXUS Liberte Post-Approval Registry

OLYMPIA Registry (Formerly OLYMPIC Registry)


Taxus Express Atom and Taxus Liberte Atom

Promus Element Everolimus-Eluting Coronary Stent System

Fig.34: Promus Element Sales by Region, Q1 2010

Taxus Element Paclitaxel-Eluting Coronary Stent System

ClearStream Technologies' Intrepide

Cordis' Cypher Products

Cypher Sales Performance

Cypher Revenue by Region, 2006-2009 (US$ million)

Fig.35: Cypher Sales by Region, 2009

Fig.36: Cypher Quarterly Sales Data, 2008-Q1 2010 (US$ million)

Cypher Clinical Studies






Patients with Multi-Vessel Disease

Cypher Select

e-SELECT Registry

Cypher Select Plus

Iberhospitex' Active and IRIST DESs

Lepu Medical's Partner Sirolimus-Eluting Stent

Medtronic's Endeavor DESs

Fig.37: Endeavor Quarterly Sales Data, Fiscal 2008-Q3 2010 (US$ million)

Endeavor Zotarolimus-Eluting Coronary Stent

Endeavor Clinical Trials

Endeavor Resolute Zotarolimus-Eluting Coronary Stent

MicroPort Medical's Firebird Rapamycin-Eluting Coronary Stent Systems

Rontis' PhoenixPico

DES Clinical Comparisons


Swedish Coronary Angiography and Angioplasty Registry

ZEST Trial: Cypher, Endeavor and Taxus Liberte


Western Denmark Heart Registry

Small Coronary Vessel Meta-Analysis

Swiss National Science Foundation Meta-Analysis

Products in Development

Atrium Medical's Cinatra Voclosporin Drug Eluting Coronary Stent System

Atrium Medical's Cinatra Corolimus-Eluting Coronary Stent System

Elixir Medical's Novolimus and Myolimus Eluting Stents

Novolimus-Eluting Stents

Myolimus-Eluting Stents

Svelte Medical Systems' SOAW DES



Aachen Resonance's ARTAX Paclitaxel-eluting Coronary Stent

Biosensors International's BioFreedom

CID's Janus Flex

CID's Optima Jet

Deutsches Herzzentrum Muenchen's Polymer-Free Dual Drug-Eluting Stent

Minvasys' Amazonia Pax Polymer-Free PES

Translumina's Yukon Choice DES+

Translumina's Yukon Choice 4


Competitive Landscape: Bioabsorbable Polymer DES Technologies

Marketed Products

Biosensors International's BioMatrix and BioMatrix Flex

LEADERS Clinical Study

eucatech's euca TAX

Eurocor's Taxcor Paclitaxel-Eluting Coronary Stent Systems

JW Medical Systems' Excel Sirolimus-Eluting Stent

Meril Life Sciences' BioMime Sirolimus Eluting Coronary Stent System

Sahajanand Medical Technologies' Supralimus and Infinnium Products

Terumo's NOBORI Stent

Vascular Concepts' ProTAXX

Products in Development

amg International's ITRIX

Blue Medical Devices' PEA Stent

Boston Scientific's Evolution Everolimus-Eluting Stent

Boston Scientific's Labcoat Element

Cordis' Cypher NEVO

Cypher NEVO Clinical Studies

DISA Vascular's Stellium

Elixir Medical's Novolimus and Myolimus Eluting Stents

Kaneka's MAHOROBA Tacrolimus-Eluting Stent

Medlogics Device's Cobra-P

Micell Technologies' MiStent

OrbusNeich's Combo Bio-engineered Sirolimus Eluting Stent

Rontis' Rapamycin-Eluting Stent


Bioabsorbable Bare Metal Stents

Arterial Remodeling Technologies' PLA Stents


Kyoto Medical Planning's IGAKI-TAMAI Stent

Bioabsorbable Drug-Eluting Stents

Abbott's Bioabsorbable DES

Bioabsorbable Therapeutics' Salix Stents

Biotronik's Absorbable Metal Stent

Elixir Medical's Myolimus-Eluting Biodegradable Stent

Reva Medical's ReZolve Bioresorbable Coronary Stent


Competitive Landscape - Bifurcation Stenting

Abbott's Multi-Link Frontier Coronary Bifurcation Stent System

Cappella's Sideguard Coronary Sidebranch Stent & Delivery System

Devax' AXXESS Biolimus A9-Eluting Bifurcation Stent System

Invatec's (Medtronic) Twin-Rail System

Medtronic's Y-Stent Bifurcation Stent

Minvasys' Nile Croco, Nile Delta and Nile Pax Bifurcation Stents

Rontis' Bifurcation Stent System

Stentys' Bifurcation Stent

TriReme Medical's Antares Coronary Stent System

Tryton Medical's Tryton Side Branch Stent System






To order this report:

Cardiovascular Devices Industry: All Change in the Coronary Stent Market

Cardiovascular Devices Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):